不同浓度盐水雾化吸入治疗毛细支气管炎临床观察#br#

Abstract
Figure/Table
References (0)
Related Citation (1)

Download: PDF (1724 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To compare the efficacy, safety and expenses of nebulized different concentration saline in treatment of hospitalized bronchiolitis. Methods: There were 66 patients enrolled in the clinical trial from January to December 2012 in the ward of Respiratory Department of the Yuying Children’s Hospital Affiliated to Wen Zhou Medical University. They were randomised to three groups, including 0.9% saline (NS) group, 3% hypertonic saline (3% HS) group and 5% hypertonic saline (5% HS) group. 0.9% normal saline solution 3 mL, 3% hypertonic saline solution 3 mL and 5% hypertonic saline solution 3 mL were given to patients in the three groups respectively, patients received nebulizations three times everyday, delivered at intervals of more than 4 h by air-compressed nebulizers and face masks until discharge. The primary efficacy outcome of the study was Clinical Bronchiolitis Severity Score, length of stay, the rate of adverse events and hospital expenses. Results: There was no significance difference in the Clinical Bronchiolitis Severity Score from the first day to the third day, neither in length of stay nor in symptom relieved time among the three groups (P>0.05). The rate of adverse events was 12.2% in 5% HS group, which was significantly higher than other two groups (2.3% in NS group, 4.6% in 3% HS group) (x2=34.199, P<0.01). The adverse events included common cough, severe cough and vomit. Conclusion: The effectiveness of nebulized hypertonic saline may not be superior to inhalation of normal saline in treatment of patients hospitalized with bronchiolitis. Nebulized hypertonic saline will not increase the medical expenses. In contrast with 5% hypertonic saline, inhalation of 3% hypertonic saline is a relative safe therapy for patients with bronchiolitiss, yet no severe adverse events have happened.

Key words： bronchiolitis hypertonic saline efficacy safety

Received: 13 January 2014

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Lili
	ZHANG Yan
	ZHANG Hailin
	ZHANG Weixi
	HU Xiaoguang
	LUO Yunchun
	LI Changchong.

URL:

https://xb.wmu.edu.cn/EN/ OR https://xb.wmu.edu.cn/EN/Y2014/V44/I12/901

[1]Smyth RL, Openshaw PJ. Bronchiolitis[J]. Lancet, 2006, 368(9532): 312-322.
[2]Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000[J]. J Pediatr, 2003, 143(5 Suppl): S127132.
[3]Zhang L, Mendoza-Sassi RA, Wainwright C, et al. Nebu-lized hypertonic saline solution for acute bronchiolitis in infants[J]. Cochrane Database Syst Rev, 2013(7): CD006458.
[4]胡亚美, 江载芳. 诸福棠实用儿科学[M]. 7版. 北京: 人民卫生出版社, 2005: 1199-1201.
[5]Wang EE, Milner RA, Navas L, et al. Observer agreement for respiratory signs and oximetry in infants hospitalized with lower respiratory infections[J]. Am Rev Respir Dis, 1992, 145(1): 106-109.
[6]Hervás D, Reina J, Yañez A, et al. Epidemiology of hospital-ization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis[J]. Eur J Clin Microbiol Infect Dis, 2012, 31(8): 1975-1981.
[7]Stockman LJ, Curns AT, Anderson LJ, et al. Respiratory syn-cytial virus-associated hospitalizations among infants and young children in theUnited States, 1997-2006[J]. Pediatr Infect Dis J, 2012, 31(1): 5-9.
[8]董琳, 张松跃, 陈小芳, 等. 儿童呼吸道合胞病毒感染的病原学及临床特点[J]. 温州医学院学报, 2005, 35(6): 490-493.
[9]Gadomski AM, Brower M. Bronchodilators for bronchiolitis[J]. Cochrane Database Syst Rev, 2010, 8(12): CD1266.
[10]Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorti-coids for acute viral bronchiolitis in infants and young children[J]. Cochrane Database Syst Rev, 2013, 6: CD4878.
[11]Sumner A, Coyle D, Mitton C, et al. Cost-effectiveness of epinephrine and dexamethasone in children with bronchiol-itis[J].Pediatrics, 2010, 126(4): 623-631.
[12]American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis[J]. Pediatrics, 2006, 118(4): 1774-1793.
[13]彭万胜, 陈信, 李冬娥, 等. 雾化吸入高渗盐水治疗婴幼儿毛细支气管炎疗效和安全性的Meta分析[J]. 中国循证儿科杂志, 2011, 6(5): 358-363.
[14]Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis:Mechanisms and rationale[J]. Pediatr Pulmonol, 2010, 45(1): 36-40.
[15]Anil AB, Anil M, Saglam AB, et al. High volume normal saline alone is as effective as nebulized salbutamol-nor-mal saline, epinephrine-normal saline, and 3% saline in mild bronchiolitis[J]. Pediatr Pulmonol, 2010, 45(1): 41-47.
[16]Luo Z, Liu E, Luo J, et al. Nebulized hypertonic saline/sal-butamol solution treatment in hospitalized children with mild to moderate bronchiolitis[J]. Pediatr Int, 2010, 52(2):199-202.
[17]洪建国, 陈强, 陈志敏, 等. 儿童常见呼吸道疾病雾化吸入治疗专家共识[J]. 中国实用儿科杂志, 2012, 27(4): 265-269.
[18]Grewal S, Ali S, McConnell DW, et al. A randomized trial of nebulized 3% hypertonic saline with epineprine in the treatment of acute bronchiolitis in the emergency department[J]. Arch Pediatr Adolesc Med, 2009, 163(11): 1007-1012.
[19]Ipek IO, Yalcin EU, Sezer RG, et al. The efﬁcacy of nebu-lized salbutamol, hypertonic saline and salbutamol/hyper-tonic saline combination in moderate bronchiolitis[J]. Pulm Pharmacol Ther, 2011, 24(6): 633-637.
[20]Everard ML, Hind D, Ugonna K, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis[J]. Thorax,2014, 69(12): 1105-1112.
[21]Ralston S, Hill V, Martinez M. Nebulized hypertonic saline without adjunctive bronchodilators for children with bronchiolitis[J]. Pediatrics, 2010, 126(3): e520-525.